Related Experiment Videos
P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study
1Department of Bone Pathology, Institute of Pathology, University of Hamburg, Germany.
General & Diagnostic Pathology
|June 1, 1997
Summary
P-glycoprotein (Pgp) is expressed in most high-grade central osteosarcomas, but its presence does not predict chemotherapy response. Pgp expression in osteosarcoma resembles that of active bone cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Multidrug resistance in cancer is often mediated by P-glycoprotein (Pgp).
- High-grade central osteosarcoma (hgc-OS) treatment response to chemotherapy varies.
- The role of Pgp in osteosarcoma tumorigenesis and chemotherapy resistance requires further characterization.
Purpose of the Study:
- To analyze Pgp expression in hgc-OS samples.
- To investigate the potential connection between Pgp and chemotherapy response in hgc-OS.
- To compare Pgp expression in hgc-OS with normal bone cells.
Main Methods:
- Immunohistochemistry was performed on 68 hgc-OS samples using the monoclonal antibody JSB-1.
- Pgp expression was analyzed in normal human epiphyseal growth plates.
- Pgp expression levels were correlated with pre- and post-chemotherapy status and treatment response.
Main Results:
- Pgp was expressed in 70.5% of hgc-OS cases.
- Post-chemotherapy samples showed a higher incidence of Pgp expression (82.9%) compared to pre-chemotherapy samples (64.4%).
- No significant correlation was found between biopsy Pgp expression and later chemotherapy response; Pgp-positive biopsies showed mixed response rates.
Conclusions:
- Pgp expression in hgc-OS partially mirrors the phenotype of active bone cells.
- The findings suggest that Pgp expression in osteosarcoma biopsies is insufficient to predict chemotherapy response.
- Further research is needed to understand Pgp's role in osteosarcoma and develop predictive markers.